Search Articles

View query in Help articles search

Search Results (1 to 1 of 1 Results)

Download search results: CSV END BibTex RIS


Clinical Benefits and Risks of Antiamyloid Antibodies in Sporadic Alzheimer Disease: Systematic Review and Network Meta-Analysis With a Web Application

Clinical Benefits and Risks of Antiamyloid Antibodies in Sporadic Alzheimer Disease: Systematic Review and Network Meta-Analysis With a Web Application

While the development of aducanumab was discontinued earlier in 2024 (January 2024) [2], lecanemab and donanemab are currently under review for approval in Europe and worldwide [3], and lecanemab is already available for patients outside of the United States, including those in the United Kingdom, Japan, China, South Korea, Israel, and the United Arab Emirates [4-6].

Danko Jeremic, Juan D Navarro-Lopez, Lydia Jimenez-Diaz

J Med Internet Res 2025;27:e68454